Watch Presentations Covering Brand New COVID-19 Research During the Symposium

On September 16, the second day of the Symposium, we'll hear from researchers presenting new findings related to COVID-19 on topics including diagnostics, vaccine strategies, and gene and cell therapies. Register for free to access these presentations!

Here's the abstract schedule for the second day:

11-11:12 a.m.—Gaurav Sahay, Ph.D., Oregon State University
Rapid generation of circulating and mucosal decoy ACE2 using mRNA nanotherapeutics for the potential treatment of SARS-CoV-2

11:12-11:24 a.m.—Paul Ayoub, University of California, Los Angeles
Improved Spike Glycoproteins to Pseuodtype Lentiviral Vectors

11:24-11:36 a.m.—Saad Khan, Ph.D., Ottawa Hospital Research Institute
Cellular Immuno-Therapy for COVID-19 induced Acute Respiratory Distress Syndrome: Design of the CIRCA-19 Trial

11:36-11:48 a.m.—Robin Hu, University of Pennsylvania
Design of conditional small interfering RNA riboswitches to identify and selectively kill cells infected with SARS-CoV-2

11:48 a.m.-12 p.m.—Chanakha Navaratnarajah, Ph.D., Mayo Clinic
SARS-CoV-2 Spike Glycoprotein Activation in Cardiomyocytes: Mechanism and Pathological Consequences

Sponsored Lunch Sessions

These companies will be hosting separate sessions from 12-1 p.m.

• Corning Life Sciences 

1-1:12 p.m.—Ami Patel, Ph.D., The Wistar Institute
A COVID-19 intradermal (ID) delivered DNA vaccine is immunogenic in multiple animal models and provides anamnestic protection in rhesus macaques against SARS-CoV-2 infection

1:12-1:24 p.m.—Mauro Giacca, M.D., Ph.D., King's College London
Approved drugs inhibiting TMEM16 proteins block SARS-CoV-2 Spike-induced cellular syncytia

1:24-1:36 p.m.—Erlinda Gordon, M.D., Cancer Center of Southern California
CORONA STUDY: DELTAREX-G, DISEASE-TARGETED GENE THERAPY, FOR COVID-19

1:36-1:48 p.m.—Kamran Miah, Ph.D., University of Oxford
Establishing A Platform For High Titre SARS-CoV-2 S Pseudotyped Lentiviral Vectors - A Tool For Anyone To Play With

1:48-2 p.m.—Arun Raturi, Ph.D., Entos Pharmaceuticals
Rapid prototyping and immunogenicity of SARS-CoV-2 DNA vaccine candidates formulated with the Fusogenix proteo-lipid vehicle delivery system

2-2:12 p.m.—Ye Liu, Ph.D., Regenxbio
Intravenously administered, AAV8-vectorized SARS-CoV2 monoclonal antibodies generate high level of serum neutralization titer in mice

2:12-2:24 p.m.—Vignesh Narayan Hariharan, Ph.D., University of Massachusetts Medical School
Developing Oligonucleotide Therapeutics for Targeted Delivery and Silencing of Conserved SARS COV-2 Gene Regions

2:24-2:36 p.m.—Nerea Zabaleta, Ph.D., Harvard Medical School, Mass Eye and Ear
AAVCOVID: Immunogenicity In Mouse And NHP Of An AAV Gene-Based SARS-CoV-2 Spike Antigen Preventative Vaccine

2:36-2:48 p.m.—BREAK

2:48-3 p.m.—Elizabeth Parzych, Ph.D., The Wistar Institute
Synthetic DNA-delivery of a SARS-CoV-2 Neutralizing Antibody with Durable In Vivo Expression and Neutralizing Activity

3-3:12 p.m.—Sabine Hauck, Ph.D., Leukocare AG
A Single-shot anti-SARS-CoV-2 Vaccine Based on a Novel Gorilla-Adenoviral Vector Stabilized in a Tailored Liquid Formulation

3:12-3:24 p.m.—Gabriel Lamothe, Laval University
ISOTHERMAL AMPLIFICATION AND DETECTION OF SARS-COV-2 USING CRISPR TECHNOLOGY

3:24-3:36 p.m.—Timothy Carey, Ph.D., Imanis Life Sciences
Safety and immunogenicity of VSV-SARS2 as a potential COVID19 vaccine: Preliminary findings in cynomolgus macaques

3:36-3:48 p.m.—Sean Sullivan, Ph.D., Arcturus Therapeutics, Inc.
Preclinical Immunogenicity Characterization of ARCT-021 SARS-CoV-2 Vaccine

​3:48-4 p.m.—Rianna Vandergaast, Ph.D., Imanis Life Sciences
Development and Validation of a High-Throughput Clinical Assay for Detecting SARS-CoV-2-Neutralizing Antibodies

4-4:12 p.m.—Ebony Gary, Ph.D., The Vaccine and Immunotherapy Center, the Wistar Institute
Preclinical Efficacy Evaluation of a DNA Vaccine Ttargeting SARS-COV-2 in a hACE2 Transduced Mouse Challenge Model

4:12-4:24 p.m.—Bartolomeo Della Ventura, University of Naples Frederico II
Fast Detection of SARS-CoV-2 in Nasal and Throat Swabs by a Simple Colorimetric Test

4:24-4:36 p.m.—Scott Sherill-Mix, University of Pennsylvania
LAMP-BEAC: Detection of SARS-CoV-2 RNA Using RT-LAMP and Molecular Beacons

4:36-4:48 p.m.—Miguel Muñoz-Alía, Ph.D., Mayo Clinic/Department of Molecular Medicine
A Serotypically Evolved Recombinant Measles Virus as a COVID-19 VaccineCandidate for High Risk/Older Individuals

4:48-5 p.m.—Wenlong Dai, Ph.D., Harvard Medical School, Mass Eye and Ear
Immunogenicity In Mice Of Nine AAV Spike-based COVID-19 Vaccine Candidates

5-5:12 p.m.—Gavin MacBeath, Ph.D., TScan Therapeutics
UNBIASED GENOME-WIDE DISCOVERY USING TSCAN REVEALS SHARED IMMUNODOMINANT CD8+ T CELL EPITOPES IN SARS-COV-2​

5:12-5:24 p.m.—Albert Chen, Broad Institute of MIT and Harvard
COVID-19 CG: Tracking SARS-CoV-2 by Mutation, Location, and Date of Interest​